Actinium-225: The ‘Rarest Drug’ Set to Revolutionize Cancer Treatment

Advantages of 225Ac Over Other Conventional and Targeted Therapies Expected to Fuel Exponential Growth Rate (over 25%) of Actinium-225 Therapy Market in the Next Decade

Targeted alpha therapy represents an emerging treatment approach that allows the possibility of bypassing the mechanism of acquired resistance in selected tumors. It attempts to deliver systemic radiation selectively to cancer cells while minimizing systemic toxic effects and may lead to additional treatment options for many cancer types

Actinium 225 (225Ac) has emerged as a potent targeted alpha therapy for various tumors with a high unmet medical need. In targeted alpha therapies, the 225Ac isotope is attached to a targeting molecule, like an antibody, which locks on a specific antigen on the cancer cell. When the isotope decays, it emits high-energy alpha particles that kill the cancer cells by causing irreparable damage, like shattering its DNA

225Ac radionuclide is gaining popularity for the treatment of various tumor entities. It has excellent nuclear properties:

• Limited range in the tissue of a few cell diameters
• High linear energy transfer leads to dense radiation damage along each alpha track
• A 10-day half-life
• Four net alpha particles emitted per decay

The favorable nuclear properties of 225Ac and its advantages over other targeted therapies are expected to boost the R&D activities and in turn, is expected to fuel the growth of the market

“Actinium is quickly becoming a premier radioisotope in cancer-targeting therapies, but its potential is limited due to its price and scarcity.”

- Chief Scientific Officer, Commercial-stage Nuclear Medicine Company, United States

Clairvoyance Research conducted an in-depth market analysis study of the Global Actinium-225 Therapy Market. The study comprehensively analyzes the market from different perspectives. It provides granular insights on hot revenue pockets, headwinds & tailwinds impacting the market, quantitative (market size & forecasts), and qualitative analysis of different segments, key strategies, and competitive landscape.

Over and above the above-mentioned coverage, the study provides comprehensive ‘Premium Insights’ on the following pointers:

• Global Volume Estimate & Forecast of Actinium-225 Radionuclide
• Pipeline Assessment
• Deep-Dive Assessment of Competitive Landscape – Covering Company Profiles (Business Overview, Financials, Pipeline, Strategic Developments) of Top 15 Players of the Market
• Assessment of Actinium-225 Therapy (Potential) Market, By Application

• Prostate Cancer
• Hematological Cancer
• Solid Tumors

• Assessment of Actinium-225 Therapy (Potential) Market, By Country/Region

• North America (US, Canada)
• Europe (Germany, UK, France and Rest of Europe)
• Asia Pacific (China, Japan, India and Rest of Asia Pacific)
• Rest of the World (Latin America, Middle-East and Africa)

For further details, please reach out to: https://www.clairvoyanceresearch.com/contact

NEED MORE?

• Talk to us about your requirements and get a customized report
• Get more details about the content of the report
• Request a Free ‘Sample Pages’ of the report